These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34970762)

  • 1. Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis-are we there yet?
    Rodrigues PM; Banales JM
    Aliment Pharmacol Ther; 2022 Jan; 55(2):247-248. PubMed ID: 34970762
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis-are we there yet? Authors' reply.
    Sorda JA; González Ballerga E; Barreyro FJ; Daruich J
    Aliment Pharmacol Ther; 2022 Jan; 55(2):249-250. PubMed ID: 34970761
    [No Abstract]   [Full Text] [Related]  

  • 3. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
    Corpechot C; Chazouillères O; Rousseau A; Le Gruyer A; Habersetzer F; Mathurin P; Goria O; Potier P; Minello A; Silvain C; Abergel A; Debette-Gratien M; Larrey D; Roux O; Bronowicki JP; Boursier J; de Ledinghen V; Heurgue-Berlot A; Nguyen-Khac E; Zoulim F; Ollivier-Hourmand I; Zarski JP; Nkontchou G; Lemoinne S; Humbert L; Rainteau D; Lefèvre G; de Chaisemartin L; Chollet-Martin S; Gaouar F; Admane FH; Simon T; Poupon R
    N Engl J Med; 2018 Jun; 378(23):2171-2181. PubMed ID: 29874528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis].
    Feng BL; Yu HH; Shen W
    Zhonghua Gan Zang Bing Za Zhi; 2019 Apr; 27(4):304-311. PubMed ID: 31082343
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bezafibrate for primary biliary cholangitis : Bezafibrate in combination with ursodeoxycholic acid in primary biliary cholangitis (BEZURSO) trial].
    Klose G; Nitschmann S
    Internist (Berl); 2018 Dec; 59(12):1344-1346. PubMed ID: 30357433
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
    Reig A; Sesé P; Parés A
    Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bezafibrate for primary biliary cirrhosis.
    Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009145. PubMed ID: 22259000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific considerations for the management of primary biliary cholangitis: are the drug treatment options good enough?
    Wetten A; Jones DEJ; Dyson JK
    Expert Opin Pharmacother; 2021 Oct; 22(15):1949-1953. PubMed ID: 34121570
    [No Abstract]   [Full Text] [Related]  

  • 9. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
    Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
    J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting liver-related serious adverse events in patients with primary biliary cholangitis-related cirrhosis treated with obeticholic acid.
    Londoño MC; Díaz-González Á
    Liver Int; 2022 Nov; 42(11):2356-2359. PubMed ID: 36162085
    [No Abstract]   [Full Text] [Related]  

  • 11. No more pilots, a phase III trial of fibrates in primary biliary cirrhosis is long overdue!
    Halliday JS; Chapman RW
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1345-6. PubMed ID: 21884243
    [No Abstract]   [Full Text] [Related]  

  • 12. In primary biliary cholangitis, adding bezafibrate to ursodeoxycholic acid increased complete biochemical response.
    Korula J
    Ann Intern Med; 2018 Oct; 169(8):JC45. PubMed ID: 30326089
    [No Abstract]   [Full Text] [Related]  

  • 13. New weapon for primary biliary cirrhosis from Japan.
    Zeniya M
    J Gastroenterol; 2003; 38(6):619-20. PubMed ID: 12858848
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial: Itching to Know: Role of Fibrates in PBC.
    Levy C; Lindor KD
    Am J Gastroenterol; 2018 Jan; 113(1):56-57. PubMed ID: 29311728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and potential treatments for primary biliary cholangitis.
    Shah RA; Kowdley KV
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):306-315. PubMed ID: 31806572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)?
    Gisbert JP; Jones EA; Pajares JM; Moreno-Otero R
    Aliment Pharmacol Ther; 2003 Jan; 17(1):17-27. PubMed ID: 12492729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bezafibrate in primary biliary cirrhosis: a pilot study.
    Ohmoto K; Mitsui Y; Yamamoto S
    Liver; 2001 Jun; 21(3):223-4. PubMed ID: 11422787
    [No Abstract]   [Full Text] [Related]  

  • 18. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
    Honda A; Ikegami T; Nakamuta M; Miyazaki T; Iwamoto J; Hirayama T; Saito Y; Takikawa H; Imawari M; Matsuzaki Y
    Hepatology; 2013 May; 57(5):1931-41. PubMed ID: 22911624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bezafibrate in Primary Biliary Cholangitis.
    Jones DE; Hegade VS
    N Engl J Med; 2018 Sep; 379(10):984. PubMed ID: 30207645
    [No Abstract]   [Full Text] [Related]  

  • 20. [Advances in the treatment of primary biliary cholangitis].
    Li YM; Wang QX; Ma X
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):805-809. PubMed ID: 29325272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.